Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line

Br J Haematol. 2021 Apr;193(2):415-419. doi: 10.1111/bjh.17372. Epub 2021 Mar 9.

Sahba Shafiee^{1

2}, Pascal Gelebart¹, Mihaela Popa^{2

3}, Monica Hellesøy², Randi Hovland⁴, Rakel Brendsdal Forthun³, Jungwoo Lee⁵, Kaoru Tohyama⁶, Anders Molven^{7

8}, Biju Parekkadan⁹, Bjørn Tore Gjertsen^{1

2

3

10}, Astrid Olsnes Kittang^{1

3}, Emmet McCormack^{1

2

10}

¹ Department of Clinical Science, Precision Oncology Research Group, University of Bergen, Bergen, Norway.
² KinN Therapeutics, Laboratory Building, Bergen University Hospital, Bergen, Norway.
³ Department of Medicine, Haukeland University Hospital, Bergen, Norway.
⁴ Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
⁵ Department of Chemical Engineering, Institute for Applied Life Sciences, University of Massachusetts, Massachusetts, USA.
⁶ Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan.
⁷ Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
⁸ Department of Pathology, Haukeland University Hospital, Bergen, Norway.
⁹ Department of Biomedical Engineering, Rutgers University and the Department of Medicine, Rutgers Biomedical and Health Sciences, Piscataway, NJ, 08854, USA.
¹⁰ Center for Cancer Biomarkers CCBIO, Bergen, Norway.

No abstract available

Keywords: MDS-L; MDS-L-2007; MDS-LGF; NSG mice; NSGS mice; hydrogel scaffold; myelodysplastic syndromes (MDS); xenograft mouse model.

Publication types